Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Cecile Courivaud, Andrew.

Slides:

Advertisements

Similar presentations

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Advertisements

LDL cholesterol in CKD—to treat or not to treat?

Treatment of acute renal failure

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Use of hemodialysis and hemoperfusion in poisoned patients

Marlies Noordzij, Kitty J. Jager Kidney International

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 79, Issue 9, Pages (May 2011)

Lipopheresis in the nephrotic syndrome

Volume 87, Issue 5, Pages (May 2015)

FGF23 or PTH: which comes first in CKD ?

C-reactive protein and dialysis access

Volume 78, Pages S10-S21 (August 2010)

Vitamin D deficiency and heart disease

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Volume 63, Pages S88-S90 (June 2003)

Volume 79, Pages S24-S27 (April 2011)

C-reactive protein and dialysis access

Volume 75, Issue 11, Pages (June 2009)

John P. Middleton, Patrick H. Pun Kidney International

Volume 77, Issue 1, Pages 6-8 (January 2010)

Volume 85, Issue 3, Pages (March 2014)

Volume 76, Pages S50-S99 (August 2009)

Comorbidity and confounding in end-stage renal disease

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 74, Issue 3, Pages (August 2008)

The need for reliable serum parathyroid hormone measurements

Nephrology Crosswords: Hemodialysis

Treatment of acute renal failure

Use of vitamin D in chronic kidney disease patients

Florian Lang, Michael Föller Kidney International

Study of Heart and Renal Protection (SHARP)

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

LDL cholesterol in CKD—to treat or not to treat?

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments R. Mishler, J.J. Sands, N.J. Ofsthun,

The calcium–phosphorus in guidelines for CKD-MBD

Blood pressure targets in hemodialysis patients

Volume 69, Issue 10, Pages (May 2006)

Volume 73, Issue 12, Pages (June 2008)

Volume 85, Issue 3, Pages (March 2014)

Effects of hemodialysis on cardiac function

Volume 83, Issue 5, Pages (May 2013)

Volume 87, Issue 3, Pages (March 2015)

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Volume 87, Issue 1, Pages (January 2015)

Starting dialysis is dangerous: how do we balance the risk?

Nephrology Crossword: Glomerulonephritis

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.

Volume 58, Issue 1, Pages (July 2000)

Fibroblast growth factor 23: the making of a hormone

Mediterranean diets: are they practical in the Western world?

Daily nocturnal home hemodialysis

Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1 Robert N. Foley, Charles A. Herzog, Allan J.

Current status of maintenance hemodialysis in Beijing, China

Volume 72, Issue 2, Pages (July 2007)

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Charles A. Herzog Kidney International

Recent developments in the management of secondary hyperparathyroidism

Increased fetuin-A levels following treatment with a vitamin D analog

Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Ellen G. Neven, Marc E. De Broe, Patrick.

Volume 74, Issue 10, Pages (November 2008)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Attributable risk for disorders of mineral metabolism.

Volume 82, Issue 1, Pages (July 2012)

Presentation transcript:

Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Cecile Courivaud, Andrew Davenport Kidney International Volume 85, Issue 1, Pages 17-20 (January 2014) DOI: 10.1038/ki.2013.301 Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 1 Cartoon proposing links between a higher mortality and hypomagnesemia/hypermagnesemia in hemodialysis patients. (a) Hypomagnesemia is commonly associated with increased co-morbidity, and also induces pro-atherosclerotic and pro-thrombotic phenotypes and mineralizing disorders. Moreover, hypomagnesemia is associated with high blood pressure and a higher risk of cardiac arrhythmia. (b) Mild hypermagnesemia may have protective vascular effects, whereas moderate hypermagnesemia reduces osteoid formation and over-supresses PTH leading to vascular calcifications. LDL chol, low-density lipoprotein cholesterol; PTH, parathyroid hormone; TG, triglycerides. Kidney International 2014 85, 17-20DOI: (10.1038/ki.2013.301) Copyright © 2014 International Society of Nephrology Terms and Conditions

Figure 2 Intra-patient variability in serum magnesium in 150 stable dialysis outpatients with 4 or more serum magnesium measurements. Data expressed as mean±s.d. Kidney International 2014 85, 17-20DOI: (10.1038/ki.2013.301) Copyright © 2014 International Society of Nephrology Terms and Conditions